Search results for "Kidney diseases"

showing 10 items of 117 documents

A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report

2012

Abstract Background Fabry disease (FD) is a hereditary metabolic disorder caused by the partial or total inactivation of a lysosomal hydrolase, the enzyme α-galactosidase A (GLA). This inactivation is responsible for the storage of undegraded glycosphingolipids in the lysosomes with subsequent cellular and microvascular dysfunction. The incidence of disease is estimated at 1:40,000 in the general population, although neonatal screening initiatives have found an unexpectedly high prevalence of genetic alterations, up to 1:3,100, in newborns in Italy, and have identified a surprisingly high frequency of newborn males with genetic alterations (about 1:1,500) in Taiwan. Case presentation We des…

lcsh:Diseases of the circulatory (Cardiovascular) systemPathologyα-galactosidase AAnderson-Fabry mutationBiopsyDNA Mutational AnalysisCase Reportmedicine.disease_causeGlobotriaosylceramide0302 clinical medicineSettore BIO/13 - Biologia ApplicataPromoter Regions Genetic0303 health sciencesMutationeducation.field_of_studymedicine.diagnostic_testbiologyMetabolic disorderMagnetic Resonance Imaging3. Good healthPhenotypeCardiovascular DiseasesDisease ProgressionFemaleKidney DiseasesRenal biopsyCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyPopulation03 medical and health sciencesPredictive Value of TestsBiopsymedicineHumansHigh resolution meltingGenetic Predisposition to Diseaseeducation030304 developmental biologyFabry diseaseAlpha-galactosidasebusiness.industrymedicine.diseaseFabry diseaseIntronslcsh:RC666-701alpha-GalactosidaseMutationGLAbiology.proteinbusiness030217 neurology & neurosurgeryKidney disease
researchProduct

Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review.

2010

Introduction Cardiovascular diseases are highly prevalent in patients with chronic kidney disease (CKD), and represent the major hazard for mortality in this population. Anomalies of left ventricular (LV) structure and function are very frequent too among CKD patients, and show a negative impact on cardiovascular prognosis. Methods We searched PubMed for manuscripts regarding left ventricular hypertrophy (LVH) in CKD. Definition of LVH was different according to different studies. Results In patients with end-stage renal disease, the prevalence of LVH is higher than 70%. Studies in patients with less advanced CKD have reported increasing prevalence of LVH along with declining renal function…

medicine.medical_specialtyAnemiaPopulationDiastoleRenal functionDiseaseurologic and male genital diseasesLeft ventricular hypertrophyKidneyRisk AssessmentVentricular Function LeftVentricular Dysfunction LeftRisk FactorsInternal medicinemedicinePrevalenceHumanscardiovascular diseasesIntensive care medicineeducationeducation.field_of_studyLeft ventricular dysfunctionbusiness.industryLeft ventricular hypertrophymedicine.diseaseChronic kidney disease.NephrologyHeart failureChronic DiseaseCardiologyDisease ProgressionKidney Failure ChronicHypertrophy Left VentricularKidney DiseasesbusinessKidney diseaseGlomerular Filtration RateJournal of nephrology
researchProduct

2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardio…

2013

1. INTRODUCTION1.1 PrinciplesThe 2013 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines continue to adhere to some fundamental principles that inspired the 2003 and 2007 guidelines, namely to base recommendations on properly conducted studies identified from an ext

medicine.medical_specialtyArterieKidney DiseasePrognosiPhysiologyCardiologyBlood PressureGuidelineRisk AssessmentDevice therapyRisk FactorsInternal medicineAntihypertensive treatmentInternal MedicineMedicineHumansIntensive care medicineLife StyleAntihypertensive Agentsbusiness.industryTask forceRisk FactorCardiovascular complicationOrgan damageArteriesCardiovascular riskLifestylePrognosisOrgan damageDevice therapyAntihypertensive AgentBlood pressureHypertensionCardiologyKidney DiseasesbusinessCardiology and Cardiovascular MedicineHumanJournal of hypertension
researchProduct

Nephro-broncho-cutaneous Fistula

1989

medicine.medical_specialtyFistulaUrinary Fistulabusiness.industryUrologyCutaneous fistulaSkin DiseasesDermatologyRadiographyHumansMedicineFemaleKidney DiseasesBronchial FistulabusinessAgedBritish Journal of Urology
researchProduct

What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatme…

2014

Percutaneous catheter-based transluminal renal denervation (RDN) has emerged as a new approach to achieve sustained blood pressure reduction in patients with drug-resistant hypertension. Experts from ESH and ESC in their recently released position papers and consensus document have summarised the current evidence, unmet needs and practical recommendations for the application of this therapeutic strategy in clinical practice. Experts of the ESH Working Group for the interventional treatment of hypertension prepared this position paper in order to provide interventionalists with guidance through the procedure of RDN. Given that there is no established intraprocedural control of ablation succe…

medicine.medical_specialtyKidney DiseasePercutaneousAblation deviceBlood PressureKidneyRenal ArterymedicineHumansIn patientKidney surgeryIntensive care medicineDenervationInterventional treatmentbusiness.industryDenervationResistant hypertensionCatheterBlood pressureHypertensionRenal denervationPosition paperKidney DiseasesCardiology and Cardiovascular MedicinebusinessHumanEuroIntervention
researchProduct

GLP-1 Receptor agonists and diabetic kidney disease: A call of attention to nephrologists

2020

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 r…

medicine.medical_specialtyMedicinaRenal functionlcsh:Medicine030209 endocrinology & metabolismReview030204 cardiovascular system & hematologyHypoglycemiaurologic and male genital diseases03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineChronic kidney diseaseMedicineMalalties cròniquesDiabetic kidney diseaseGlycemicKidneyProteinuriaKidney diseasesbusiness.industrylcsh:RType 2 Diabetes MellitusGeneral Medicinemedicine.diseasediabetic kidney diseasemedicine.anatomical_structureChronic diseasesMalalties del ronyómedicine.symptombusinessGLP-1chronic kidney diseaseKidney disease
researchProduct

Factores de predicción de dosificación inadecuada de rivaroxabán utilizando la ecuación de CKD-EPI

2021

Yes

medicine.medical_specialtyPatientsCKD-EPI:Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders [Medical Subject Headings]Dosislcsh:RC870-923:Anatomy::Cardiovascular System::Blood Vessels::Arteries::Aorta [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]DosageRivaroxabanRivaroxabánmedicineRenal insufficiency chronicInsuficiencia renal crónicaGynecology:Diseases::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency Chronic [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Observational Study as Topic [Medical Subject Headings]business.industry:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Dosage Calculations [Medical Subject Headings]lcsh:Diseases of the genitourinary system. Urology:Persons::Persons::Patients [Medical Subject Headings]NephrologyPacientesDosificaciónbusiness:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Prescriptions [Medical Subject Headings]Nefrología
researchProduct

Transitional cell carcinoma of the renal pelvis presenting as a renal abscess.

2002

We report on a 76-year-old woman who was diagnosed with a primary renal abscess of the left kidney. After percutaneous drainage, no clinical improvement was observed. Surgical exploration and nephrectomy were performed. The histologic evaluation revealed an unsuspected transitional cell carcinoma of the renal pelvis, which had been misinterpreted as a primary renal abscess. Malignancy must be considered as an underlying cause for the formation of a renal abscess, especially if no other predisposing factors such as diabetes mellitus or urinary stones are present.

medicine.medical_specialtyPercutaneousUrologymedicine.medical_treatmentUrinary systemUrologyurologic and male genital diseasesMalignancyDiagnosis DifferentialDiabetes mellitusmedicineHumansKidney PelvisAgedUltrasonographyCarcinoma Transitional Cellbusiness.industryUrographymedicine.diseaseNephrectomyAbscessKidney NeoplasmsRenal Abscessmedicine.anatomical_structureTransitional cell carcinomaFemaleKidney DiseasesRadiologybusinessTomography X-Ray ComputedRenal pelvisUrology
researchProduct

Left ventricular hypertrophy: not so much determinant of renal outcome?

2011

medicine.medical_specialtyPhysiologyProportional hazards modelbusiness.industryChronic kidney diseases.Renal functionLeft ventricular hypertrophyLeft ventricular hypertrophymedicine.diseaseOutcome (game theory)Chronic diseaseInternal medicineInternal MedicinemedicineCardiologyCardiology and Cardiovascular Medicinebusiness
researchProduct

Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction.

2021

Introduction and objectives: Urinary sodium (UNa+) has emerged as a useful biomarker of poor clinical outcomes in acute heart failure (AHF). Here, we sought to evaluate: a) the usefulness of a single early determination of UNa+ for predicting adverse outcomes in patients with AHF and renal dysfunction, and b) whether the change in UNa+ at 24 hours (Delta UNa24 h) adds any additional prognostic information over baseline values. Methods: This is a post-hoc analysis of a multicenter, open-label, randomized clinical trial (IMPROVE-HF) (ClinicalTrials.gov NCT02643147) that randomized 160 patients with AHF and renal dysfunction on admission to a) the standard diuretic strategy, or b) a carbohydra…

medicine.medical_specialtyRenal failureTratamiento diuréticoAntígeno carbohidrato 125medicine.medical_treatmentRenal function030204 cardiovascular system & hematologyInsuficiencia cardiaca agudaGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInterquartile rangeInternal medicineBiomarker-guided therapyEnsayo clínicoTerapia guiada por biomarcadoresClinical endpointHumansMedicineDiureticsAgedAged 80 and overHeart Failurebusiness.industryFallo renalSodiumAcute heart failureGeneral Medicinemedicine.diseaseClinical trialClinical trialAcute heart failure Antígeno carbohidrato 125 Biomarker-guided therapy Carbohydrate antigen 125 Clinical trial Diuretic treatment Ensayo clínico Fallo renal Insuficiencia cardiaca aguda Renal failure Terapia guiada por biomarcadores Tratamiento diuréticoCarbohydrate antigen 125Heart failureAcute DiseaseDiuretic treatmentBiomarker (medicine)Kidney DiseasesDiureticbusiness
researchProduct